ESMO - European Society for Medical Oncology
@myesmo.bsky.social
The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
Can less mean more? Immunotherapy changed #CancerCare — but access remains unequal. Dose optimisation may help make treatment sustainable and equitable. Equity starts with evidence. #ESMODailyReporter 📌 https://ow.ly/fT1450XZX20
January 20, 2026 at 10:00 AM
Can less mean more? Immunotherapy changed #CancerCare — but access remains unequal. Dose optimisation may help make treatment sustainable and equitable. Equity starts with evidence. #ESMODailyReporter 📌 https://ow.ly/fT1450XZX20
👉 Early rates close 21 Jan for #ELCC26. Join the #ThoracicOncology meeting in Copenhagen, 25–28 March 2026 (onsite & online)
Practice‑oriented updates and multidisciplinary exchange.
🔗 Secure your seat: https://ow.ly/YIJq50XZXlC
Practice‑oriented updates and multidisciplinary exchange.
🔗 Secure your seat: https://ow.ly/YIJq50XZXlC
January 20, 2026 at 9:15 AM
👉 Early rates close 21 Jan for #ELCC26. Join the #ThoracicOncology meeting in Copenhagen, 25–28 March 2026 (onsite & online)
Practice‑oriented updates and multidisciplinary exchange.
🔗 Secure your seat: https://ow.ly/YIJq50XZXlC
Practice‑oriented updates and multidisciplinary exchange.
🔗 Secure your seat: https://ow.ly/YIJq50XZXlC
📣 #ESMOBreast26: One week left to share your studies! The field of breast cancer research is advancing rapidly — and your work can help shape the next breakthroughs.
⏰ Deadline: 27 January 2026
🔗 https://ow.ly/ieY350XX7b1
#esmomeetings
⏰ Deadline: 27 January 2026
🔗 https://ow.ly/ieY350XX7b1
#esmomeetings
January 19, 2026 at 6:00 AM
📣 #ESMOBreast26: One week left to share your studies! The field of breast cancer research is advancing rapidly — and your work can help shape the next breakthroughs.
⏰ Deadline: 27 January 2026
🔗 https://ow.ly/ieY350XX7b1
#esmomeetings
⏰ Deadline: 27 January 2026
🔗 https://ow.ly/ieY350XX7b1
#esmomeetings
📣 #ESMOGynae26: A comprehensive scientific and educational programme designed to support clinicians and researchers in delivering optimal care for patients. Abstract submission system now open!
⏰Deadline 31 March 2026
🔗 https://ow.ly/QNBR50XWGx3
#esmomeetings
⏰Deadline 31 March 2026
🔗 https://ow.ly/QNBR50XWGx3
#esmomeetings
January 16, 2026 at 7:45 AM
📣 #ESMOGynae26: A comprehensive scientific and educational programme designed to support clinicians and researchers in delivering optimal care for patients. Abstract submission system now open!
⏰Deadline 31 March 2026
🔗 https://ow.ly/QNBR50XWGx3
#esmomeetings
⏰Deadline 31 March 2026
🔗 https://ow.ly/QNBR50XWGx3
#esmomeetings
As a worldwide community of over 50,000 #OncologyProfessionals, we look ahead to 2026, continuing to connect, disseminate #science, and advance #CancerCare.
January 15, 2026 at 2:02 PM
As a worldwide community of over 50,000 #OncologyProfessionals, we look ahead to 2026, continuing to connect, disseminate #science, and advance #CancerCare.
#GenderMedicine ≠ women’s health. Misconceptions persist due to sex & gender data gaps in #ClinicalTrials and poor reporting. Integrating these factors is vital for fair, evidence-based care.
More in the #ESMODailyReporter 📌 https://ow.ly/Ha6P50XX5B0
More in the #ESMODailyReporter 📌 https://ow.ly/Ha6P50XX5B0
January 15, 2026 at 9:30 AM
#GenderMedicine ≠ women’s health. Misconceptions persist due to sex & gender data gaps in #ClinicalTrials and poor reporting. Integrating these factors is vital for fair, evidence-based care.
More in the #ESMODailyReporter 📌 https://ow.ly/Ha6P50XX5B0
More in the #ESMODailyReporter 📌 https://ow.ly/Ha6P50XX5B0
⏰ Early registration for #ESMOTAT26 ends 28 Jan!
Join a leading multi-stakeholder forum on cancer #drugdiscovery in Paris.
🔗 Register now: https://ow.ly/VQce50XWy9H
#ESMOMeetings #targetedtherapies #PrecisionMedicine #ClinicalTrials
Join a leading multi-stakeholder forum on cancer #drugdiscovery in Paris.
🔗 Register now: https://ow.ly/VQce50XWy9H
#ESMOMeetings #targetedtherapies #PrecisionMedicine #ClinicalTrials
January 14, 2026 at 3:01 PM
⏰ Early registration for #ESMOTAT26 ends 28 Jan!
Join a leading multi-stakeholder forum on cancer #drugdiscovery in Paris.
🔗 Register now: https://ow.ly/VQce50XWy9H
#ESMOMeetings #targetedtherapies #PrecisionMedicine #ClinicalTrials
Join a leading multi-stakeholder forum on cancer #drugdiscovery in Paris.
🔗 Register now: https://ow.ly/VQce50XWy9H
#ESMOMeetings #targetedtherapies #PrecisionMedicine #ClinicalTrials
Radiomics + real-world data improve survival prediction in stage IV #NSCLC on immunotherapy. A study in ESMO Real World Data & Digital Oncology shows ML models outperform PD-L1. Read Rodrigo Dienstmann in the #ESMODailyReporter #HealthAI 🔗 https://ow.ly/hzzj50XVYbH
January 13, 2026 at 10:01 AM
Radiomics + real-world data improve survival prediction in stage IV #NSCLC on immunotherapy. A study in ESMO Real World Data & Digital Oncology shows ML models outperform PD-L1. Read Rodrigo Dienstmann in the #ESMODailyReporter #HealthAI 🔗 https://ow.ly/hzzj50XVYbH
👉 Hear from leading voices on why ESMO Sarcoma and Rare Cancers 2026 is essential for anyone working on rare cancers and sarcomas.
⏰ Early registration closes tomorrow - 14 January—secure your seat now! #ESMORareCancers26
🔗 buff.ly/fEWQ3Nw
⏰ Early registration closes tomorrow - 14 January—secure your seat now! #ESMORareCancers26
🔗 buff.ly/fEWQ3Nw
January 13, 2026 at 8:01 AM
👉 Hear from leading voices on why ESMO Sarcoma and Rare Cancers 2026 is essential for anyone working on rare cancers and sarcomas.
⏰ Early registration closes tomorrow - 14 January—secure your seat now! #ESMORareCancers26
🔗 buff.ly/fEWQ3Nw
⏰ Early registration closes tomorrow - 14 January—secure your seat now! #ESMORareCancers26
🔗 buff.ly/fEWQ3Nw
📣 #ELCC26: Last chance to share your research!
⏰ Abstract deadline: tomorrow, Tuesday, 13 January, 21:00 CET
🔗 Submit now: https://ow.ly/3RmJ50XVuzK
Join global experts shaping the future of #ThoracicOncology. Your work belongs on this stage. #LungCancer #esmomeetings
⏰ Abstract deadline: tomorrow, Tuesday, 13 January, 21:00 CET
🔗 Submit now: https://ow.ly/3RmJ50XVuzK
Join global experts shaping the future of #ThoracicOncology. Your work belongs on this stage. #LungCancer #esmomeetings
January 12, 2026 at 2:02 PM
📣 #ELCC26: Last chance to share your research!
⏰ Abstract deadline: tomorrow, Tuesday, 13 January, 21:00 CET
🔗 Submit now: https://ow.ly/3RmJ50XVuzK
Join global experts shaping the future of #ThoracicOncology. Your work belongs on this stage. #LungCancer #esmomeetings
⏰ Abstract deadline: tomorrow, Tuesday, 13 January, 21:00 CET
🔗 Submit now: https://ow.ly/3RmJ50XVuzK
Join global experts shaping the future of #ThoracicOncology. Your work belongs on this stage. #LungCancer #esmomeetings
New prospective data from #ESMOAsia25 show that in MRI-positive #ProstateCancer, TB+iSB is non-inferior to standard TB+SB, potentially streamlining diagnosis and reducing unnecessary biopsy cores.
#ESMODailyReporter 📌 https://ow.ly/5hUa50XTkno
#ESMODailyReporter 📌 https://ow.ly/5hUa50XTkno
January 9, 2026 at 10:00 AM
New prospective data from #ESMOAsia25 show that in MRI-positive #ProstateCancer, TB+iSB is non-inferior to standard TB+SB, potentially streamlining diagnosis and reducing unnecessary biopsy cores.
#ESMODailyReporter 📌 https://ow.ly/5hUa50XTkno
#ESMODailyReporter 📌 https://ow.ly/5hUa50XTkno
#MCCRWorkshop: applications are still open, don’t miss your chance
One intensive week to sharpen #ClinicalTrialDesign with guidance from leading investigators
Apply now: https://ow.ly/nzes50XTRRx
⏰Apply by 30 January 2026
📅13–18 June 2026
European Organisation for Research and Treatment of Cancer
One intensive week to sharpen #ClinicalTrialDesign with guidance from leading investigators
Apply now: https://ow.ly/nzes50XTRRx
⏰Apply by 30 January 2026
📅13–18 June 2026
European Organisation for Research and Treatment of Cancer
January 9, 2026 at 9:30 AM
#MCCRWorkshop: applications are still open, don’t miss your chance
One intensive week to sharpen #ClinicalTrialDesign with guidance from leading investigators
Apply now: https://ow.ly/nzes50XTRRx
⏰Apply by 30 January 2026
📅13–18 June 2026
European Organisation for Research and Treatment of Cancer
One intensive week to sharpen #ClinicalTrialDesign with guidance from leading investigators
Apply now: https://ow.ly/nzes50XTRRx
⏰Apply by 30 January 2026
📅13–18 June 2026
European Organisation for Research and Treatment of Cancer
📣 #ELCC26: Abstract submissions close Tuesday, 13 January.
Share your work, join the conversation, and shape the future.
🔗 https://ow.ly/NOzw50XN4y5
Your research can spark change in #LungCancer care. #ELCC26 is the stage for innovation and collaboration. Don’t miss it!
Share your work, join the conversation, and shape the future.
🔗 https://ow.ly/NOzw50XN4y5
Your research can spark change in #LungCancer care. #ELCC26 is the stage for innovation and collaboration. Don’t miss it!
January 8, 2026 at 2:00 PM
📣 #ELCC26: Abstract submissions close Tuesday, 13 January.
Share your work, join the conversation, and shape the future.
🔗 https://ow.ly/NOzw50XN4y5
Your research can spark change in #LungCancer care. #ELCC26 is the stage for innovation and collaboration. Don’t miss it!
Share your work, join the conversation, and shape the future.
🔗 https://ow.ly/NOzw50XN4y5
Your research can spark change in #LungCancer care. #ELCC26 is the stage for innovation and collaboration. Don’t miss it!
KANDLELIT-001:As presented at #ESMOAsia25, the next-generation KRAS G12C inhibitor MK-1084 continues to show manageable safety and encouraging antitumour activity in advanced #CRC, as monotherapy and in combination regimens.
#ESMODailyReporter 📌 https://ow.ly/hkAI50XTkiQ
#ESMODailyReporter 📌 https://ow.ly/hkAI50XTkiQ
January 8, 2026 at 10:35 AM
KANDLELIT-001:As presented at #ESMOAsia25, the next-generation KRAS G12C inhibitor MK-1084 continues to show manageable safety and encouraging antitumour activity in advanced #CRC, as monotherapy and in combination regimens.
#ESMODailyReporter 📌 https://ow.ly/hkAI50XTkiQ
#ESMODailyReporter 📌 https://ow.ly/hkAI50XTkiQ
📣 #ESMOBreast26: Last days to share your research! Gain unparalleled visibility by presenting your work to clinicians, researchers, and decision-makers from across the globe.
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 buff.ly/gpGvyJI
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 buff.ly/gpGvyJI
January 7, 2026 at 10:03 AM
📣 #ESMOBreast26: Last days to share your research! Gain unparalleled visibility by presenting your work to clinicians, researchers, and decision-makers from across the globe.
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 buff.ly/gpGvyJI
⏰ Submit your abstract by 27 January 2026
#esmomeetings
🔗 buff.ly/gpGvyJI
📣 The future of GI oncology is written together. Registration is now open for the ESMO Gastrointestinal Cancers Congress 2026, taking place in Munich, Germany, 1–4 July. A global stage for science, education and collaboration. #ESMOGI26 #esmomeetings
🔗 buff.ly/HNkIEuN
🔗 buff.ly/HNkIEuN
December 30, 2025 at 8:01 AM
📣 The future of GI oncology is written together. Registration is now open for the ESMO Gastrointestinal Cancers Congress 2026, taking place in Munich, Germany, 1–4 July. A global stage for science, education and collaboration. #ESMOGI26 #esmomeetings
🔗 buff.ly/HNkIEuN
🔗 buff.ly/HNkIEuN
🎉 50 years. 50,000 professionals. Advancing #oncology
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
December 29, 2025 at 1:01 PM
🎉 50 years. 50,000 professionals. Advancing #oncology
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
📣 #ESMOBreast26: Join global experts in Berlin, and online, to explore cutting-edge research in breast cancer care – registration system now open!
⏰ Benefit from big savings if you register before 26 February 2026
🔗 https://ow.ly/seSv50XMxzn
⏰ Benefit from big savings if you register before 26 February 2026
🔗 https://ow.ly/seSv50XMxzn
December 29, 2025 at 8:30 AM
📣 #ESMOBreast26: Join global experts in Berlin, and online, to explore cutting-edge research in breast cancer care – registration system now open!
⏰ Benefit from big savings if you register before 26 February 2026
🔗 https://ow.ly/seSv50XMxzn
⏰ Benefit from big savings if you register before 26 February 2026
🔗 https://ow.ly/seSv50XMxzn
ML& DL models can predict DFS and OS after neoadjuvant chemotherapy in HR+/HER2- #BreastCancer using routine data. A study suggests interpretable models may perform well without complex data.
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
December 22, 2025 at 3:20 PM
ML& DL models can predict DFS and OS after neoadjuvant chemotherapy in HR+/HER2- #BreastCancer using routine data. A study suggests interpretable models may perform well without complex data.
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
Read the commentary by Rodrigo Dienstmann
#HealthAI #ESMODailyReporter 🔗 https://ow.ly/H9xQ50XN2Nh
👉 #ELCC26 unites every discipline in #ThoracicOncology. Intimate yet truly global. In this clip, Natasha Leighl explains why that mix matters and why ELCC is a global meeting to reach a broader audience
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
December 22, 2025 at 8:45 AM
👉 #ELCC26 unites every discipline in #ThoracicOncology. Intimate yet truly global. In this clip, Natasha Leighl explains why that mix matters and why ELCC is a global meeting to reach a broader audience
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
🔗 Submit your abstract: buff.ly/99EQAgt
⏰ 13 Jan 2026 (21:00 CET)
In the #ESMODailyReporter, Umberto Malapelle explains how concomitant analysis of DNA and RNA can advance cancer characterisation and guide clinical decision making, highlighting data presented at #ESMOAsia25
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
December 19, 2025 at 10:30 AM
In the #ESMODailyReporter, Umberto Malapelle explains how concomitant analysis of DNA and RNA can advance cancer characterisation and guide clinical decision making, highlighting data presented at #ESMOAsia25
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
📣 #ELCC26: Your new data deserves a global platform
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
December 19, 2025 at 8:31 AM
📣 #ELCC26: Your new data deserves a global platform
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
Submit your abstract now 🔗 buff.ly/a44FfwT
@drjnaidoo.bsky.social addresses the community, underscoring the value of contributing to shared progress in #ThoracicOncology
⏰ 13 Jan 2026 (21:00 CET)
📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer:
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
December 18, 2025 at 2:33 PM
📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer:
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
✅New imaging modalities: Improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 https://ow.ly/jwA650XLs1q
Developing guidance in #AI is challenging as technology evolves rapidly. ESMO task forces have developed long-lasting recommendations to support the responsible use of AI in #oncology. Read more in the #ESMODailyReporter 📌 https://ow.ly/XonL50XLkVg
#HealthAI #DigitalOncology
#HealthAI #DigitalOncology
December 18, 2025 at 1:20 PM
Developing guidance in #AI is challenging as technology evolves rapidly. ESMO task forces have developed long-lasting recommendations to support the responsible use of AI in #oncology. Read more in the #ESMODailyReporter 📌 https://ow.ly/XonL50XLkVg
#HealthAI #DigitalOncology
#HealthAI #DigitalOncology
📢 Applications open for the #MCCRworkshop!
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch
December 18, 2025 at 8:00 AM
📢 Applications open for the #MCCRworkshop!
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
🔗 Apply now: https://ow.ly/gV7t50XHtgU
📅 13–18 June 2026
✅ Apply by 30 January #ClinicalTrial #ClinicalResearch